©The Author(s) 2025.
World J Diabetes. Dec 15, 2025; 16(12): 111963
Published online Dec 15, 2025. doi: 10.4239/wjd.v16.i12.111963
Published online Dec 15, 2025. doi: 10.4239/wjd.v16.i12.111963
Table 3 Mendelian randomization analysis of associations of plasma proteins with diabetic neuropathy in replicated stage (United Kingdom biobank pharma proteomics project vs genome-wide association studies Finngen)
| Outcome | Exposure | Method | nSNP | Beta | SE | P value |
| DN | HSPA1B | Inverse variance weighted | 2 | 3.696 | 2.072 | 0.074 |
| DN | SCGN | Wald ratio | 1 | -0.938 | 0.346 | 0.007 |
| DN | MICB | Inverse variance weighted | 29 | -0.187 | 0.001 | 0.008 |
| DN | WARS | Inverse variance weighted | 3 | 0.482 | 0.168 | 0.004 |
| DN | BRD2 | (-) | - | - | - | - |
| DN | CSNK2B | (-) | - | - | - | - |
| DN | PSMB9 | (-) | - | - | - | - |
| DN | BTN3A1 | (-) | - | - | - | - |
| DN | NOTUM | (-) | - | - | - | - |
- Citation: Ding XF, Dang X, Lin S. Identification of novel therapeutic targets for diabetic neuropathy through integrated proteomics and transcriptomics approaches. World J Diabetes 2025; 16(12): 111963
- URL: https://www.wjgnet.com/1948-9358/full/v16/i12/111963.htm
- DOI: https://dx.doi.org/10.4239/wjd.v16.i12.111963